摘要 |
The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of <SUP>13</SUP>CO<SUB>2 </SUB>exhaled by the subject upon intravenous or oral administration of a <SUP>13</SUP>C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite <SUP>13</SUP>CO<SUB>2 </SUB>in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.
|